Format

Send to

Choose Destination
Urol Oncol. 2016 Nov;34(11):487.e13-487.e20. doi: 10.1016/j.urolonc.2016.06.012. Epub 2016 Aug 11.

Associations between long-term serum platinum and neurotoxicity and ototoxicity, endocrine gonadal function, and cardiovascular disease in testicular cancer survivors.

Author information

1
Depatement of Clinical Medicine, Arctic University of Tromsø, Tromsø, Norway; Department of Oncology, University Hospital of North Norway, Tromsø, Norway. Electronic address: line.v.hjelle@uit.no.
2
Depatement of Clinical Medicine, Arctic University of Tromsø, Tromsø, Norway; Department of Oncology, University Hospital of North Norway, Tromsø, Norway.
3
Department of Clinical Pharmacology, St. Olavs University Hospital, Trondheim, Norway.
4
Department of Oncology, Oslo University Hospital, Oslo, Norway.
5
Department of Oncology and Medical Physics, Haukeland University Hospital, Bergen, Norway.
6
The cancer Clinic, St. Olavs University Hospital, Trondheim, Norway.
7
Institute of Community Medicine, Arctic University of Tromsø, Tromsø, Norway.
8
Department of Oncology, Oslo University Hospital, Oslo, Norway; Medical faculty, University of Oslo, Oslo, Norway; Cancer Registry of Norway, Oslo, Norway.
9
Department of Oncology, Oslo University Hospital, Oslo, Norway; Medical faculty, University of Oslo, Oslo, Norway.

Abstract

OBJECTIVE:

To evaluate the associations between long-term serum levels of platinum (se-Pt) and neurotoxicity and ototoxicity (NTX), endocrine gonadal function (endocrine-GF), and cardiovascular disease (CVD) in testicular cancer survivors.

MATERIAL AND METHODS:

A total of 292 cisplatin-treated testicular cancer survivors (1980-1994) participated in a national follow-up study (2007-2008). Se-Pt was quantified by inductively coupled plasma mass spectrometry, and categorized in quartiles. Symptoms of NTX were assessed with scale for chemotherapy-induced neurotoxicity (SCIN), with each symptom in 4 categories and total SCIN score categorized in quartiles. Endocrine-GF was categorized according to cutoff values for the 25, 50, and 75 percentiles of luteinizing hormone (LH) and testosterone within each decadal age group established from a control group. CVD was defined as ischemic heart disease, stroke, or artery occlusion. Associations between se-Pt levels and NTX, endocrine-GF, or risk for CVD, were analyzed with ordinal logistic regression and Cox regression, respectively.

RESULTS:

Median follow-up was 19 years (range: 13-28). In ordinal regression analyses, increasing quartiles of se-Pt were significantly associated with increasing quartiles of SCIN (P for trend = 0.05), increased tinnitus (P<0.001), and increased hearing impairment (P = 0.04). The association remained significant for tinnitus when adjusting for cisplatin dose. Increasing LH quartiles was associated with increasing se-Pt quartiles (P = 0.04). No association between se-Pt in quartiles and CVD was established.

CONCLUSION:

Median 19 years after treatment, increasing quartiles of se-Pt are associated with increasing SCIN score, tinnitus, hearing impairment, and increasing LH levels. However, these associations remained significant only for tinnitus and LH when adjusting for administered cisplatin dose.

KEYWORDS:

Cisplatin retention; Long-term follow-up; Testicular cancer

PMID:
27523611
DOI:
10.1016/j.urolonc.2016.06.012
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science Icon for Norwegian BIBSYS system
Loading ...
Support Center